Issuer Free Writing Prospectus

Filed Pursuant to Rule 433

Registration No. 333-189395

July 29, 2013

2

EXPLANATORY NOTE:

The

attached

pages

update

the

corporate

presentation

filed

as

an

issuer

free

writing

prospectus

on

July

22,

2013:

•

Slide

16,

number

of

patients

identified

above

the

left

graph

for

Percent

Brain

Volume

Change

at

Week

52:

–

n=32 corresponds with bar showing -0.04 percent brain volume change; and

–

n=18 corresponds with bar showing -0.32 percent brain volume change.

[Note:  the corporate presentation prior to this update

had the patient numbers (i.e.,

n=32 and n=18) reversed.]

•

Slide

16,

number

of

patients

identified

below

the

right

graph

for

Annualized

Relapse

Rate

(ARR)

at

Week

52: 

–

n=32 corresponds with bar showing 0.28 ARR; and

–

n=18 corresponds with bar showing 0.63 ARR.

[Note:  the corporate presentation prior to this update

had the patient numbers (i.e.,

n=32 and n=18) reversed.]

•

Slide

17,

ARR

below

the

middle

graph

is

>

1.

[Note:

the

corporate

presentation

prior

to

this

update

reflected     

“>1”

rather than “>1.”]

•

Slide

22,

65

patients

were

enrolled

in

the

Abili-T

trial

at

July

19,

2013.

[Note:

the

corporate

presentation

prior

to

this

update

reflected

53

patients

enrolled

at

June

14,

2013.]

3

TERMS Study -

Prospective Analysis in

More Active or Progressive Patients

Sub-population of patients (n=50) with more progressed/active disease profile (baseline

ARR >1) most closely mirrors SPMS patients

88% Reduction in

Brain Atrophy

Percent Brain Volume Change

at Week 52

Statistically Significant

Improvement in Disability (p=0.045)

55% Reduction in ARR

Annualized Relapse Rate (ARR)

at Week 52

Change in Disability (EDSS)

at Week 52

These

Data

Support

Phase

IIb

Program

in

SPMS

4

TERMS Study -

Subgroup Analysis

in Patients Naïve to DMT

Annualized relapse rate in DMT naïve populations.  ARR in placebo subjects without previous disease modifying

treatment (DMT) experience reflects relapse rates commonly seen in other placebo controlled trials in MS. In this

subpopulation,

treatment

with

Tcelna™

resulted in a

56–73% reduction  in ARR compared with  placebo.

64% Reduction

p=0.046

73% Reduction

p=0.009

56% Reduction

p=0.060

n=25

n=45

n=8

n=16

n=28

n=53

mITT

ARR > 1

ARR>1

Tcelna

Placebo

0

0.2

0.4

0.6

0.8

1

1.2

1.4

0.21

0.18

0.31

0.48

0.5

1.18

5

Abili-T

: Landmark trial in SPMS

•

Abili-T Phase IIb clinical trial in SPMS is ongoing

–

Double-blind, 1:1 randomized, placebo-controlled

–

Inclusion criteria: Secondary Progressive MS with EDSS of 3 to 6

–

65 patients enrolled at July 19, 2013

–

Immune Monitoring program conducted on a blinded basis

•

Fast Track designation granted by FDA for Tcelna in SPMS

•

180 Patients expected to be enrolled

–

SPMS population

–

30 sites in USA and Canada

•

2 annual courses of personalized therapy